Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A vision for the future?

M Baum1

  • 1Department of Psycho-oncology, University College London Medical School, UK.

British Journal of Cancer
|March 20, 2002
PubMed
Summary
This summary is machine-generated.

Systemic adjuvant therapy, including endocrine treatments like goserelin, offers new options for early breast cancer patients. These therapies aim to prevent distant recurrence and improve treatment choices across different patient groups.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the MRL diagnostics dengue fever virus IgM capture ELISA and the PanBio Rapid Immunochromatographic Test for diagnosis of dengue fever in Jamaica.

Journal of clinical microbiology·1999
Same author

Plasma lycopene concentrations in humans are determined by lycopene intake, plasma cholesterol concentrations and selected demographic factors.

The Journal of nutrition·1999
Same author

Allelic variation at (TAA)n microsatellite loci in a world collection of chickpea (Cicer arietinum L.) germplasm.

Molecular & general genetics : MGG·1999
Same author

Somatic growth in infant heart transplant recipients.

Pediatric transplantation·1999
Same author

Breast screening. Informed consent for mammographic screening.

BMJ (Clinical research ed.)·1999
Same author

NHS breast screening programme. Money may be better spent on symptomatic women.

BMJ (Clinical research ed.)·1999
Same journal

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

British journal of cancer·2026
Same journal

Altretamine induces ferroptosis in small cell lung cancer by promoting epigenetic silencing and lysosomal degradation of GPX4.

British journal of cancer·2026
Same journal

Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.

British journal of cancer·2026
Same journal

De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study.

British journal of cancer·2026
Same journal

Planetary Health Diet Index and breast cancer risk.

British journal of cancer·2026
Same journal

Can national lung cancer screening programs be implemented without exacerbating social disparities?

British journal of cancer·2026
See all related articles

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Systemic adjuvant therapy is crucial after primary tumor removal in early breast cancer to prevent distant metastases.
  • Endocrine therapies have significantly advanced for systemic adjuvant treatment.
  • Ovarian ablation is effective but not always suitable for young pre- and perimenopausal women.

Purpose of the Study:

  • To evaluate novel endocrine therapies for systemic adjuvant treatment in early breast cancer.
  • To explore reversible medical ovarian suppression as an alternative to ovarian ablation.
  • To assess the potential of new agents like anastrozole and fulvestrant in early-stage disease.

Main Methods:

  • Review of international clinical trials and treatment guidelines.

Related Experiment Videos

  • Evaluation of endocrine agents including luteinizing hormone-releasing hormone agonists (goserelin), anastrozole, and fulvestrant.
  • Analysis of treatment efficacy and tolerability in pre-, peri-, and postmenopausal breast cancer patients.

    • Main Results:

    • Goserelin (Zoladex) offers a reversible medical ovarian suppression option for pre- and perimenopausal patients.
    • International trials support goserelin as a valuable addition to adjuvant therapies.
    • Anastrozole (Arimidex) and fulvestrant show promise in advanced disease, with ongoing trials (ATAC) investigating their role in early breast cancer.

    Conclusions:

    • Medical ovarian suppression with goserelin is an attractive alternative for young patients.
    • Anastrozole and fulvestrant may offer further management options for early breast cancer.
    • These endocrine agents are expected to expand treatment choices for a broad spectrum of early breast cancer patients.